Home
Therapeutics
Infectious Disease

Infectious Diseases

Leading the Charge Against Infectious Diseases

Leading Infectious Disease Research

hVIVO provides unparalleled scientific capability in respiratory infectious disease research, underpinned by decades of virology expertise and a comprehensive suite of validated Human Challenge Models across influenza, RSV, hMPV, HRV, COVID19 and other priority pathogens. Supported by BSL2 and BSL3 facilities, inhouse model development, manufacturing and integrated early phase clinical and laboratory operations, our platform enables precise characterisation of host–pathogen dynamics and high resolution evaluation of novel vaccines and therapeutics.

World leader in Human Challenge Trials with models for influenza, RSV, hMPV, HRV, COVID‑19, Influenza, and Malaria

Expanded capabilities beyond respiratory diseases to pathogens including Dengue, Zika, Norovirus, and Bordetella pertussis.

State‑of‑the‑art Human Challenge Unit facility with Containment Level 3 (BSL‑3) and onsite BSL‑3 labs.

Over 80+ Human Challenge Studies delivered, including the first SARS‑CoV‑2 challenge study, and the only commercially available fully characterised models for hMPV, RSV-B and Omicron

Infectious Disease Capabilities

Pathogen & Model Development or Selection

Discover our available models and how to develop a customised model

virus-image (2)

Facilities & Infrastructure

Including BSL2 & BSL3

hVIVO_Vaccine_Research2

Multifaceted Infectious Disease Laboratory

Including, Molecular, Immunology, Virology and Bacteria

hVIVO_Lab_Services_ELISpot-1

Human Challenge

World-leaders in human challenge studies

A Catchpole Presenting to Audience

Infectious Disease eBOOk

Infectious Disease eBook

Covering CMC consulting, regulatory strategy, scientific guidance through to clinical operations

Scientific PublicationPharmaceuticalClinical pharmacologyAll cardiometabolicDiabetesHepaticMAFLD

Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: Impact on pharmacokinetics and drug–drug interactions

Scientific PublicationAll cardiometabolicDiabetesHepaticCardiometabolicMAFLD

Novel pharmacotherapies for weight loss: Understanding the role of incretins to enable weight loss and improved health outcomes

BlogArticleTrial designAll cardiometabolicPhase IDiabetesCardiometabolicobesity

Selecting the Right Endpoints for Early-Phase Cardiometabolic Trials

FAQ

Get in touch with us

What infectious disease areas does hVIVO have the strongest scientific expertise in?

hVIVO’s scientific leadership is anchored in respiratory infectious diseases, supported by decades of virology expertise and a broad portfolio of validated Human Challenge Models—including influenza, RSV, hMPV, HRV, COVID19 and other priority pathogens.

What laboratory and facility infrastructure supports hVIVO’s infectious disease research?

hVIVO operates advanced Containment Level 2 and Level 3 (BSL2 / BSL3) clinical and laboratory facilities, including a stateoftheart Human Challenge Unit and onsite BSL3 laboratories.
These facilities are complemented by a multifaceted infectious disease laboratory covering molecular, bacteriology, immunology and virology platforms.

FAQ 3: How does hVIVO support end-to-end development of vaccines and therapeutics?

hVIVO delivers comprehensive early phase development support, from pathogen/model selection and protocol design through to full regulatory alignment and execution of Human Challenge Studies.
This integrated clinical laboratory ecosystem enables high resolution evaluation of host–pathogen dynamics and accelerates data generation for novel vaccines and therapeutics